Senate debate intensifies on medical cannabidiol bill as sponsors defend technical and regulatory approach

Third-substitute Senate Bill 89, addressing medical cannabidiol policy and related regulatory authority, drew extended floor debate on technical language, public-health safeguards and the structure of oversight bodies.

Sponsor Senator Vickers described SB 89 as a complex bill that pulls together many technical items and gives agencies flexibility to adopt rules tailored to the details: "We give [the agencies] flexibility to do that," he said, while urging colleagues that the regulatory framework is intended to address technical issues. Several senators raised objections and requested more time or additional studies. Senator Madsen, for example, said she had outstanding questions about removing medical professionals from the Controlled Substances Advisory Board and replacing some seats with law enforcement representatives; she urged more complete evidence and study before advancing major changes.

Other senators asked about the status of companion bills and the possibility of merging related measures; the sponsor said he was willing to meet privately with colleagues to work through outstanding technical concerns and to consider circling the bill if the body preferred more time for study. The transcript records motion activity and roll-call procedures for this and other bills on the floor, but does not record a final amended text in this excerpt.

The floor exchange recorded multiple requests for clarity on scientific evidence, advisory-board membership and oversight but does not resolve those questions in the provided excerpt; the sponsor offered to continue discussions off the floor.

Next procedural steps were not finalized on the floor within the provided transcript; the sponsor invited private meetings and said he would work with other senators to address concerns before further action.